PTEN restrains SHH medulloblastma growth through cell autonomous and nonautonomous mechanisms
Curation statements for this article:-
Curated by eLife
eLife Assessment
This valuable study provides insights into the role of Pten mutations in SHH-medulloblastoma, by using mouse models to resolve the effects of heterozygous vs homozygous mutations on proliferation and cell death throughout tumorigenesis. The experiments presented are convincing, with rigorous quantifications and orthogonal experimentation provided throughout, and the models employing sporadic oncogene induction, rather than EGL-wide genetic modifications, represent an advancement in experimental design. However, the study remains limited, such that the biological conclusions do not extend greatly from those in the extant literature. This could be addressed with additional experimentation focused on cell cycle kinetic changes at early stages, as well as greater characterization of macrophage phenotypes (e.g., microglia vs circulating monocytes). The work will be of interest to medical biologists studying general cancer mechanisms, as the function of Pten may be similar across tumor types.
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (eLife)
Abstract
A third of patients with the pediatric cerebellar tumor Medulloblastoma (MB) have mutations that activate Sonic hedgehog (SHH) signaling (SHH-MB subgroup). The contribution of secondary mutations to tumor severity, however is not clear. PTEN mutations are enriched in the SHH-1 subtype that has the lowest survival rate. Widespread heterozygous loss of Pten in two SHH-MB mouse models increases penetrance and excellerates onset of differentiated tumors. We delineated cellular and transcriptional changes that accelerate tumor growth and cause differentiation using a sporadic SHH-MB mouse model expressing oncogenic SmoM2 in rare cerebellar granule cell precursors (GCPs) and scRNA-seq analysis. Homozygous but not heterozygous sporadic loss of Pten resulted in rapid acceleration of tumor growth and end stage disease by 40 days, compared to ∼25% survival in control SmoM2 mice at 100 days. Heterozygous PTEN mutations therefore should negatively impact disease outcome primarily with germline mutations. Loss of Pten in normal or SmoM2-expressing GCPs increased proliferation and enhanced progenitor state initially but by 12 days Pten mutant SmoM2 tumors were highly differentiated due to increased survival of non-proliferating GCPs. Furthermore, macrophage infiltration and cytotoxicity were reduced in differentiated regions of tumors lacking Pten, indicating cell nonautonomous changes also contribute to accelerated tumor growth.
Article activity feed
-
-
-
eLife Assessment
This valuable study provides insights into the role of Pten mutations in SHH-medulloblastoma, by using mouse models to resolve the effects of heterozygous vs homozygous mutations on proliferation and cell death throughout tumorigenesis. The experiments presented are convincing, with rigorous quantifications and orthogonal experimentation provided throughout, and the models employing sporadic oncogene induction, rather than EGL-wide genetic modifications, represent an advancement in experimental design. However, the study remains limited, such that the biological conclusions do not extend greatly from those in the extant literature. This could be addressed with additional experimentation focused on cell cycle kinetic changes at early stages, as well as greater characterization of macrophage phenotypes (e.g., microglia vs …
eLife Assessment
This valuable study provides insights into the role of Pten mutations in SHH-medulloblastoma, by using mouse models to resolve the effects of heterozygous vs homozygous mutations on proliferation and cell death throughout tumorigenesis. The experiments presented are convincing, with rigorous quantifications and orthogonal experimentation provided throughout, and the models employing sporadic oncogene induction, rather than EGL-wide genetic modifications, represent an advancement in experimental design. However, the study remains limited, such that the biological conclusions do not extend greatly from those in the extant literature. This could be addressed with additional experimentation focused on cell cycle kinetic changes at early stages, as well as greater characterization of macrophage phenotypes (e.g., microglia vs circulating monocytes). The work will be of interest to medical biologists studying general cancer mechanisms, as the function of Pten may be similar across tumor types.
-
Reviewer #1 (Public review):
Summary:
This paper investigates how Pten loss influences the development of medulloblastoma using mouse models of Shh-driven MB. Previous studies have shown that Pten heterozygosity can accelerate tumorigenesis in models where the entire GNP compartment has MB-promoting mutations, raising questions about how Pten levels and context interact, especially when cancer-causing mutations are more sporadic. Here, the authors create an allelic series combining sporadic, cell-autonomous induction of SmoM2 with Pten loss in granule neuron progenitors. In their models, Pten heterozygosity does not significantly impact tumor development, whereas complete Pten loss accelerates tumour onset. Notably, Pten-deficient tumours accumulate differentiated cells, reduced cell death, and decreased macrophage infiltration. At …
Reviewer #1 (Public review):
Summary:
This paper investigates how Pten loss influences the development of medulloblastoma using mouse models of Shh-driven MB. Previous studies have shown that Pten heterozygosity can accelerate tumorigenesis in models where the entire GNP compartment has MB-promoting mutations, raising questions about how Pten levels and context interact, especially when cancer-causing mutations are more sporadic. Here, the authors create an allelic series combining sporadic, cell-autonomous induction of SmoM2 with Pten loss in granule neuron progenitors. In their models, Pten heterozygosity does not significantly impact tumor development, whereas complete Pten loss accelerates tumour onset. Notably, Pten-deficient tumours accumulate differentiated cells, reduced cell death, and decreased macrophage infiltration. At early stages, before tumour establishment, they observe EGL hyperplasia and more pre-tumour cells in S phase, leading them to suggest that Pten loss initially drives proliferation but later shifts towards differentiation and accumulation of death-resistant, postmitotic cells. Overall, this is a well-executed and technically elegant study that confirms and extends earlier findings with more refined models. The phenotyping is strong, but the mechanistic insight is limited, especially with respect to dosage effects and macrophage biology.
Strengths:
The work is carefully executed, and the models-using sporadic oncogene induction rather than EGL-wide genetic manipulations-represent an advance in experimental design. The deeper phenotyping, including single-cell RNA-seq and target validation, adds rigor.
Weaknesses:
The biological conclusions largely confirm findings from previous studies (Castellino et al, 2010; Metcalf et al, 2013), showing that germline or conditional Pten heterozygosity accelerates tumorigenesis, generates tumors with a very similar phenotype, including abundant postmitotic cells, and reduced cell death.
The second stated goal - to understand why Pten dosage might matter - remains underdeveloped. The difference between earlier models using EGL-wide SmoA1 or Ptch loss versus sporadic cell-autonomous SmoM2 induction and Pten loss in this study could reflect model-specific effects or non-cell-autonomous contributions from Pten-deficient neighbouring cells in the EGL, for example. However, the study does not explore these possibilities. For instance, examining germline Pten loss in the sporadic SmoM2 context could have provided insight into whether dosage effects are cell-autonomous or dependent on the context.
The observations on macrophages are intriguing but preliminary. The reduction in Iba1+ cells could reflect changes in microglia, barrier-associated macrophages, or infiltrating peripheral macrophages, but these populations are not distinguished. Moreover, the functional relevance of these immune changes for tumor initiation or progression remains unexplored.
-
Reviewer #2 (Public review):
The authors sought to answer several questions about the role of the tumor suppressor PTEN in SHH-medulloblastoma formation. Namely, whether Pten loss increases metastasis, understanding why Pten loss accelerates tumor growth, and the effect of single-copy vs double-copy loss on tumorigenesis. Using an elegant mouse model, the authors found that Pten mutations do not increase metastasis in a SmoD2-driven SHH-medulloblastoma mouse model, based on extensive characterization of the presence of spinal cord metastases. Upon examining the cellular phenotype of Pten-null tumors in the cerebellum, the authors made the interesting and puzzling observation that Pten loss increased the differentiation state of the tumor, with fewer cycling cells, seemingly in contrast to the higher penetrance and decreased latency of …
Reviewer #2 (Public review):
The authors sought to answer several questions about the role of the tumor suppressor PTEN in SHH-medulloblastoma formation. Namely, whether Pten loss increases metastasis, understanding why Pten loss accelerates tumor growth, and the effect of single-copy vs double-copy loss on tumorigenesis. Using an elegant mouse model, the authors found that Pten mutations do not increase metastasis in a SmoD2-driven SHH-medulloblastoma mouse model, based on extensive characterization of the presence of spinal cord metastases. Upon examining the cellular phenotype of Pten-null tumors in the cerebellum, the authors made the interesting and puzzling observation that Pten loss increased the differentiation state of the tumor, with fewer cycling cells, seemingly in contrast to the higher penetrance and decreased latency of tumor growth.
The authors then examined the rate of cell death in the tumor. Interestingly, Pten-null tumors had fewer dying cells, as assessed by TUNEL. In addition, the tumors expressed differentiation markers NeuN and SyP, which are rare in SHH-MB mouse models. This reduction in dying cells is also evident at earlier stages of tumor growth. By looking shortly after Pten-loss induction, the authors found that Pten loss had an immediate impact on increasing the proliferative state of GCPs, followed by enhancing the survival of differentiated cells. These two pro-tumor features together account for the increased penetrance and decreased latency of the model. While heterozygous loss of Pten also promoted proliferation, it did not protect against cell death.
Interestingly, loss of Pten alone in GCPs caused an increase in cerebellar size throughout development. The authors suggest that Pten normally constrains GCP proliferation, although they did not check whether reduced cell death is also contributing to cerebellum size.
Lastly, the authors examined macrophage infiltration and found that there was less macrophage infiltration in the Pten-null tumors. Using scRNA-seq, they suggest that the observed reduction in macrophages might be due to an immunosuppressive tumor microenvironment.
This mouse model will be of high relevance to the medulloblastoma community, as current models do not reflect the heterogeneity of the disease. In addition, the elegant experimentation into Pten function may be relevant to cancer biologists outside of the medulloblastoma field.
Strengths:
The in-depth characterisation of the mouse model is a major strength of the study, including multiple time points and quantifications. The single-cell sequencing adds a nice molecular feature, and this dataset may be relevant to other researchers with specific questions of Pten function.
Weaknesses:
One weakness of the study was the examination of the macrophage phenotype, which did not include quantification (only single images), so it is difficult to assess whether this reduction of macrophages holds true across multiple samples. Future studies will also be needed to assess whether Pten-mutated patient medulloblastomas also have a differentiation phenotype, but this is difficult to assess given the low number of samples worldwide.
-
